Business Standard

Gland Pharma makes decent debut, shares end at 21% premium vs issue price

The Rs 6,480-crore IPO of Gland Pharma managed to sail through solely on the back of institutional investor demand.

Image courtesy: Fresenius Kabi
Premium

Gland Pharma is one of the largest and fastest-growing injectable-focused B2B companies. (Representative image) Image courtesy: Fresenius Kabi

SI Reporter Mumbai
Shares of Gland Pharma made a decent debut on the bourses on Friday. On BSE, the stock opened at Rs 1,701, 13 per cent higher against its issue price of Rs 1,500 per share. Later, it moved higher to Rs 1,850 in the intra-day trade before settling at Rs 1,820, a 21 per cent premium against the issue price. A combined 12.9 million shares changed hands on the counter on the National Stock Exchange (NSE) and BSE. In comparison, the S&P BSE Sensex was up 0.65 per cent at 43,882 points.

The Rs 6,480-crore initial public offering (IPO) of Gland

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Nov 20 2020 | 10:03 AM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com